Age disparities in SGLT2 inhibitor prescription among people with type 2 diabetes: The role of frailty and sex
Fuente:
Wiley Open Access
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Artículo Open Access |
| Published: |
Wiley
2026
|
| Subjects: | |
| Online Access: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1867006433812283392 |
|---|---|
| author | Changyuan Yang Petra Denig Lynne Chepulis Ryan G. Paul Jung‐Im Shin Ron T. Gansevoort Priya Vart |
| author_facet | Changyuan Yang Petra Denig Lynne Chepulis Ryan G. Paul Jung‐Im Shin Ron T. Gansevoort Priya Vart Changyuan Yang Petra Denig Lynne Chepulis Ryan G. Paul Jung‐Im Shin Ron T. Gansevoort Priya Vart |
| collection | Wiley Open Access |
| contents | Age disparities in SGLT2 inhibitor prescription among people with type 2 diabetes: The role of frailty and sex Changyuan Yang Petra Denig Lynne Chepulis Ryan G. Paul Jung‐Im Shin Ron T. Gansevoort Priya Vart Diabetes, Obesity and Metabolism Abstract Background Older adults with type 2 diabetes (T2DM) are less likely to receive sodium–glucose cotransporter‐2 (SGLT2) inhibitors, despite their proven cardio‐renal benefits and safety. Whether this age‐related gap is driven by frailty, sex, or other factors remains unclear. Methods This observational study analysed data from adults registered in primary care during 2023, using the Groningen Initiative to Analyse Type 2 Diabetes Treatment (GIANTT) database. Eligibility for SGLT2 inhibitor treatment was determined based on the Dutch College of General Practitioners (NHG) guideline for T2DM. Prescription rates were assessed across demographics, comorbidities, and preceding medication use. Multivariable logistic regression models were used to assess the association of age and identify factors associated with SGLT2 inhibitor prescriptions. Results Among 10 241 adults with T2DM, 41% ( n = 4223) were eligible for SGLT2 inhibitor prescription. The prescription rate in the overall population was 15.2% and among eligible people was 25.5%. In people eligible for SGLT2 inhibitors, prescription rates were markedly lower with increasing age, with 37.6% in those aged <60 years, 32.1% in 60–69 years, 27.2% in 70–79 years, and only 13.7% in those aged ≥80 years. In multivariable analysis, compared with those aged <60 years, individuals aged 70–79 and ≥80 were associated with significantly decreased likelihood of SGLT2 inhibitor prescription, independent of frailty and other relevant covariates [odds ratio (OR): 0.56, 95%CI: 0.43–0.72] and (OR: 0.22, 95%CI: 0.16–0.30), respectively. Age disparities in SGLT2 inhibitor prescription were evident across subgroups, including different levels of frailty and both sexes, with disparities particularly pronounced in females compared with males ( p interaction = 0.01). Females had lower prescription rates than males across age groups and levels of frailty. Conclusions SGLT2 inhibitor prescription rates among Dutch adults with T2DM were low, with persistent age‐ and sex‐related disparities independent of frailty, highlighting the need for equitable prescribing. 10.1111/dom.70421 http://creativecommons.org/licenses/by-nc/4.0/ |
| doi_str_mv | 10.1111/dom.70421 |
| format | Artículo Open Access |
| id | wiley_oa_10_1111_dom_70421 |
| institution | Wiley Open Access |
| license_str_mv | http://creativecommons.org/licenses/by-nc/4.0/ |
| publishDate | 2026 |
| publisher | Wiley |
| record_format | wiley_oa |
| spellingShingle | Age disparities in SGLT2 inhibitor prescription among people with type 2 diabetes: The role of frailty and sex Changyuan Yang Petra Denig Lynne Chepulis Ryan G. Paul Jung‐Im Shin Ron T. Gansevoort Priya Vart Diabetes, Obesity and Metabolism Age disparities in SGLT2 inhibitor prescription among people with type 2 diabetes: The role of frailty and sex Changyuan Yang Petra Denig Lynne Chepulis Ryan G. Paul Jung‐Im Shin Ron T. Gansevoort Priya Vart Diabetes, Obesity and Metabolism Abstract Background Older adults with type 2 diabetes (T2DM) are less likely to receive sodium–glucose cotransporter‐2 (SGLT2) inhibitors, despite their proven cardio‐renal benefits and safety. Whether this age‐related gap is driven by frailty, sex, or other factors remains unclear. Methods This observational study analysed data from adults registered in primary care during 2023, using the Groningen Initiative to Analyse Type 2 Diabetes Treatment (GIANTT) database. Eligibility for SGLT2 inhibitor treatment was determined based on the Dutch College of General Practitioners (NHG) guideline for T2DM. Prescription rates were assessed across demographics, comorbidities, and preceding medication use. Multivariable logistic regression models were used to assess the association of age and identify factors associated with SGLT2 inhibitor prescriptions. Results Among 10 241 adults with T2DM, 41% ( n = 4223) were eligible for SGLT2 inhibitor prescription. The prescription rate in the overall population was 15.2% and among eligible people was 25.5%. In people eligible for SGLT2 inhibitors, prescription rates were markedly lower with increasing age, with 37.6% in those aged <60 years, 32.1% in 60–69 years, 27.2% in 70–79 years, and only 13.7% in those aged ≥80 years. In multivariable analysis, compared with those aged <60 years, individuals aged 70–79 and ≥80 were associated with significantly decreased likelihood of SGLT2 inhibitor prescription, independent of frailty and other relevant covariates [odds ratio (OR): 0.56, 95%CI: 0.43–0.72] and (OR: 0.22, 95%CI: 0.16–0.30), respectively. Age disparities in SGLT2 inhibitor prescription were evident across subgroups, including different levels of frailty and both sexes, with disparities particularly pronounced in females compared with males ( p interaction = 0.01). Females had lower prescription rates than males across age groups and levels of frailty. Conclusions SGLT2 inhibitor prescription rates among Dutch adults with T2DM were low, with persistent age‐ and sex‐related disparities independent of frailty, highlighting the need for equitable prescribing. 10.1111/dom.70421 http://creativecommons.org/licenses/by-nc/4.0/ |
| title | Age disparities in SGLT2 inhibitor prescription among people with type 2 diabetes: The role of frailty and sex |
| topic | Diabetes, Obesity and Metabolism |
| url | https://dom-pubs.pericles-prod.literatumonline.com/doi/10.1111/dom.70421 |